OTLK today
$0.45-$0.03 (-6.96%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $0.55
Key levels
Resistance$0.55
Resistance$0.49
Support$0.41
Support$0.28
Latest news & SEC filings
LegalOutlook Therapeutics asks CMS for a billing code for LYTENAVA
All OTLK news →About Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company that develops and sells an eye-injectable version of bevacizumab, branded LYTENAVA, for treating a retinal condition called wet age-related macular degeneration. The medicine is authorized in the European Union and the United Kingdom, and the company is seeking approval in the United States. It launched the product in Germany and the UK in 2025 and intends to commercialize directly in the U.S. if cleared. The company is also studying the treatment for diabetic macular edema and branch retinal vein occlusion.
Based on the company's 10-K filed Dec 19, 2025.
Nasdaq · Healthcare
Outlook Therapeutics, Inc. (OTLK)
What Is the Price Target for OTLK?
SEPT Low Target
$1.60
SEPT Mid Target
$4.00
SEPT High Target
$4.00
Analyst Consensus
$4.00
Is OTLK a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for OTLK.
Start Free Trial →Is OTLK Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$4.00
32
Moat Score
NONE
3/9
Piotroski Score
-59.1
Altman Z-Score
What Is Smart Money Doing with OTLK?
Insider Signal
BUYING
6 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Haddadin Yezan Munther | director | Buy | 29,000 | $24K | Jun 2, 2026 |
| Sukhtian Ghiath M. | director 10% owner | Buy | 8,539,709 | $5.0M | May 28, 2026 |
| Sukhtian Faisal Ghiath | director | Buy | 122,174 | $50K | May 27, 2026 |
| Haddadin Yezan Munther | director | Buy | 34,000 | $15K | May 26, 2026 |
| THURMAN RANDY H | director | Buy | 5,000 | $2K | May 26, 2026 |
| HILZINGER KURT J | director | Buy | 400,000 | $177K | May 26, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →OTLK Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
55.91%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for OTLK
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for OTLK, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:54:18 | $0.45 | 1,612 | $$721 | BUY |
| 16:54:09 | $0.45 | 3,150 | $$1K | SELL |
| 16:49:33 | $0.45 | 2,035 | $$910 | SELL |
| 16:39:15 | $0.45 | 2,057 | $$917 | SELL |
| 16:36:57 | $0.45 | 8,300 | $$4K | BUY |
5 dark pool trades shown · $$8K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Outlook Therapeutics, Inc. (OTLK) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →OTLK — frequently asked questions
What is OTLK stock price today?
Outlook Therapeutics, Inc. (OTLK) is at $0.45, down 6.96% (-$0.03) at the Nov 12, 2026 close.
Why is OTLK stock moving today?
Latest OTLK news — Oct 1, 2026: Outlook Therapeutics asks CMS for a billing code for LYTENAVA
What is the OTLK price target?
The average analyst price target for OTLK is $4.00, ranging from $2 to $4, based on 3 analysts.
What do analysts rate OTLK?
Analyst ratings for OTLK: 1 Buy, 4 Hold, 1 Sell — consensus Hold.
Did OTLK beat earnings?
OTLK last reported on Aug 12, 2026: EPS -$0.09 vs -$0.08 expected — a miss of 12.5%.
What are OTLK support and resistance levels?
Support: $0.41, $0.28, $0.21. Resistance: $0.49, $0.55, $0.60.
What are insiders doing with OTLK?
Insider activity: BUYING, 6 buys and 0 sells in the last 90 days.
What is the latest news on OTLK?
Oct 1, 2026: Outlook Therapeutics asks CMS for a billing code for LYTENAVA